News

Press Release
    Option:
    Press Release
    Archive
      Option:
      Archive

      Active Filters

      S1404 QoL results
      Nov 23, 2022
      Patients with high-risk melanoma had better quality of life on pembrolizumab than on standard immunotherapy regimens
      SWOG Results at SABCS 2022
      Nov 21, 2022
      SWOG researchers will present 10 abstracts at SABCS 2022. Here are highlights.
      Stratification factors can reduce statistical power
      Nov 3, 2022
      Adding stratification factors can reduce a small trial’s statistical power
      S1801 Melanoma Results at ESMO 2022
      Sep 11, 2022
      SWOG researchers have found that starting pembrolizumab before surgery instead of waiting until after surgery significantly improves the outlook for patients with stage III-IV melanoma.
      S0931 EVEREST results at ASCO 2022
      Jun 3, 2022
      S0931 found everolimus after surgery tended to increase recurrence-free survival time in patients with high-risk kidney cancer, although results narrowly missed reaching statistical significance
      Lung-MAP S1800A results at ASCO 2022
      Jun 3, 2022
      Ramucirumab plus pembrolizumab combination reduced risk of death by 31 percent compared to standard of care in patients with advanced non-small cell lung cancer that had progressed on prior immunotherapy.
      ACA Medicaid Expansion and SWOG Trial Participants
      Jun 1, 2022
      Affordable Care Act’s expansion of Medicaid in 2014 was followed by a significant rise in proportion of enrollees in group’s cancer trials insured by Medicaid.